Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
Executive Summary
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.
You may also be interested in...
Amgen Resolves Repatha Access Kerfuffle With Express Scripts
On eve of congressional hearing, the pharmacy benefit manager assures Amgen that Repatha is available to its employees.
What Will Happen When Rebates Go Away? Look At Authorized Generics
Recent launches by Lilly, Amgen and Gilead suggest list prices may decrease with the HHS proposal to disrupt the rebate system, but not as low as current net prices after rebates, according to pharmacy benefit experts.
CVS ‘Guaranteed Net Cost’ Program Is Alternative To High Price/High Rebate Model
Program likely to generate fewer rebates so it remains to be seen whether payers will embrace the new model in a big way.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
